Skye Bioscience director granted 75,000 stock options
Skye Bioscience director Paul A. Grayson received a grant of stock options for 75,000 shares of Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Skye Bioscience director Paul A. Grayson received a grant of stock options for 75,000 shares of Common Stock. The options have an exercise price of $0.615 per share and expire on March 31, 2036. The award vests in equal monthly installments over one year beginning March 31, 2026, and represents his full reported option holdings from this filing.
Insider Trade Summary
Grant/Award: 75,000 shares
Grant/Award
1 txn
Insider
Grayson Paul A.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 75,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 75,000 contracts (Direct)
Footnotes (1)
- F1. The stock option vests in equal monthly installments over the one year period beginning March 31, 2026.
Key Figures
Options granted: 75,000 options
Exercise price: $0.615 per share
Total options after grant: 75,000 options
+3 more
6 metrics
Options granted
75,000 options
Stock Option (Right to Buy) covering Common Stock
Exercise price
$0.615 per share
Exercise price for 75,000-share option grant
Total options after grant
75,000 options
Total derivative securities owned following transaction
Expiration date
March 31, 2036
Option term end date for the grant
Vesting period start
March 31, 2026
Monthly vesting over one year beginning this date
Underlying shares
75,000 shares
Common Stock underlying the stock option
Key Terms
Stock Option (Right to Buy), Common Stock, exercise price, expiration date, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Common Stock financial
"underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
exercise price financial
"conversion_or_exercise_price: "0.6150""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-03-31T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vests in equal monthly installments financial
"The stock option vests in equal monthly installments over the one year period"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Skye Bioscience (SKYE) director Paul A. Grayson report in this Form 4?
Paul A. Grayson reported receiving a grant of stock options for 75,000 shares of Skye Bioscience Common Stock. These options give him the right to buy shares at a fixed price, subject to a vesting schedule and expiration date disclosed in the filing.
How many Skye Bioscience (SKYE) stock options were granted to Paul A. Grayson?
Paul A. Grayson was granted stock options covering 75,000 shares of Skye Bioscience Common Stock. This entire 75,000-share amount is shown as his total option holdings following the transaction, indicating the grant created his reported derivative position in this filing.
What is the exercise price of Paul A. Grayson’s Skye Bioscience (SKYE) stock options?
The stock options granted to Paul A. Grayson have an exercise price of $0.615 per share. This means he can purchase Skye Bioscience Common Stock at $0.615 for each share underlying the option, once the options have vested and before they expire.
When do Paul A. Grayson’s Skye Bioscience (SKYE) options vest?
The stock options vest in equal monthly installments over a one-year period beginning March 31, 2026. Each month a portion becomes exercisable, gradually increasing the number of shares he may purchase at the fixed exercise price during the vesting year.
When do the Skye Bioscience (SKYE) stock options granted to Paul A. Grayson expire?
The options granted to Paul A. Grayson expire on March 31, 2036. After that expiration date, any unexercised portion of the 75,000-share award can no longer be used to buy Skye Bioscience Common Stock at the $0.615 exercise price.
Was Paul A. Grayson’s Skye Bioscience (SKYE) Form 4 a market purchase or a compensation grant?
The Form 4 reflects a grant or award acquisition of derivative securities, not an open-market purchase. The transaction code “A” and description indicate a stock option award, with no reported cash purchase of existing shares on the open market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates